Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03193645|
Recruitment Status : Completed
First Posted : June 21, 2017
Last Update Posted : February 26, 2019
The DUO study's main objective is to evaluate, in the real life, the prevalence of cardiovascular risk in patients with prostate cancer that hormone treatment of androgen suppression by Degarelix was introduced.
This study will also assess, at the initiation of therapy, the prevalence of osteoporosis, metabolic comorbidities, depression, sexual and geriatric patients suffering from prostate cancer.
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Drug: Degarelix|
|Study Type :||Observational|
|Actual Enrollment :||150 participants|
|Official Title:||Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)|
|Actual Study Start Date :||June 27, 2017|
|Actual Primary Completion Date :||June 30, 2018|
|Actual Study Completion Date :||January 31, 2019|
Other Name: Firmagon
- Occurrence of cardiovascular comorbidity [ Time Frame: At inclusion ]Measured by a history of at least one cardiovascular illness (according to ICD-10) and/or at least three cardiovascular risk factors (as defined by Cancer Committee of the French Urology Association)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03193645
|Hopital de la Source (there may be multiple sites in this country)|
|Study Director:||Global Clinical Compliance||Ferring Pharmaceuticals|